View Post

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: biospace.com Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options. Genprex has no affiliation with these …

View Post

Cancer accounts for more than one-quarter of new drug approvals, analysis finds

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com Overall, the report, from the Tufts Center for the Study of Drug Development, found that new cancer drug approvals since 2010 have increased by 4 percent since the 1980s. More than one-quarter of the drugs that have received Food and Drug Administration approval have been for cancers, according to a new analysis. The analysis, by …

View Post

Amgen’s drug targeting ‘undruggable’ protein shines at lung cancer conference

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com Amgen presented data for the KRAS G12C inhibitor AMG 510 at the World Conference on Lung Cancer in Barcelona, showing a 54 percent response rate among patients receiving the pivotal study dose. A drug in development for a protein target once thought unreachable by pharmaceutical means has new data showing its potential efficacy in lung …

View Post

Novel Approaches Push the Envelope in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jessica Hergert From: onclive.com Developments in antibody-drug conjugates (ADCs), TKIs, and neoadjuvant interventions are improving outcomes for patients with early- and advanced-stage HER2-positive breast cancer, said Douglas K. Marks, MD, adding that investigational approaches could expand the treatment armamentarium even further. “For the treating oncologists, the options to offer patients who previously had a very poor prognosis are becoming …

View Post

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: yahoo.com – 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint) – – Treatment emergent adverse events Grade 3 or higher were reported by 10 of 25 patients (safety as primary endpoint) – Ipsen (Euronext: IPN; ADR: IPSEY) and Servier announced today initial safety and …

View Post

Preclinical study reveals the impact of age on immunotherapy treatment for breast cancer

In Clinical Trials by Barbara Jacoby

Source: Brigham and Women’s Hospital From: eurekalert.org Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient’s immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer (TNBC). Despite the fact that most breast cancer …

View Post

World’s First Clinical Trial to Ease Pain of Cancer Patients

In Clinical Trials by Barbara Jacoby

Dr. Yaacov Richard Lawrence, a London-born and educated doctor, is part of a unique team of Radiation Oncology specialists at Sheba Medical Center, conducting the world’s first  clinical trial and study of targeted radiation treatments into the solar plexus (the main abdominal artery), to relieve excruciating pain and prolong the lives of critically ill pancreatic cancer patients. Other members of the …

View Post

FDA Grants Breakthrough Device Designation to the Prescient Metabiomics LifeKit® Prevent Test for the Early Detection of Colon Polyps and Colon Cancer

In Clinical Trials by Barbara Jacoby

Source: Prescient Medicine From: PR Newswire Prescient Metabiomics, a privately held company and a subsidiary of Prescient Medicine Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted the company’s submission for Breakthrough Device designation to its LifeKit® Prevent Colorectal Neoplasia Test. This Breakthrough Device designation is the first designation for a non-invasive diagnostic test that is designed to …

View Post

FAK protein linked to chemotherapy resistance in ovarian cancer

In Clinical Trials by Barbara Jacoby

Source: University of California – San Diego From: sciencedaily.com Although the number of women being diagnosed and dying of ovarian cancer is declining, recurrence, drug resistance and mortality remain high for women with high-grade serous ovarian carcinoma, the most common form of epithelial ovarian cancer. A new study in the journal eLife by University of California San Diego School of …

View Post

USPSTF recommends preventive drugs for women at high breast cancer risk

In Clinical Trials by Barbara Jacoby

By: Nelson HD, et al. JAMA. 2019;doi:10.1001/jama.2019.5780. Pace, LE, et al. JAMA. 2019;doi:10.1001/jama.2019.9689. USPSTF. JAMA. 2019;doi:10.1001/jama.2019.11885. From: healio.com The U.S. Preventive Services Task Force today recommended that clinicians offer breast cancer risk-reducing medications such as tamoxifen, raloxifene and aromatase inhibitors to asymptomatic women aged 35 years and older who are at elevated risk for developing the disease and low risk …